论文部分内容阅读
检测Ｆａｓ、ＦａｓＬ在上皮性卵巢癌及其肿瘤浸润淋巴细胞（ＴＩＬ）中的表达，探讨Ｆａｓ系统在卵巢癌免疫逃逸中的作用。方法：用流式细胞术检测了３１份上皮性卵巢癌、２０份卵巢良性肿瘤、１０份正常卵巢组织以及３１份卵巢癌ＴＩＬ、１２份卵巢良性肿瘤ＴＩＬ的Ｆａｓ及ＦａｓＬ的表达。结果：卵巢癌组织的Ｆａｓ表达明显低于卵巢良性肿瘤及正常卵巢组织（Ｐ＜０．０１），其ＦａｓＬ表达则明显高于后者（Ｐ＜０．０１）；卵巢良性肿瘤及正常组织的Ｆａｓ、Ｆａｓ Ｌ表达无差异（Ｐ＞０．０５）。卵巢癌组织中含有丰富的ＴＩＬ，其Ｆａｓ及ＦａｓＬ的表达明显高于卵巢良性肿瘤ＴＩＬ，差异有显著性（Ｐ＞０．０５）。卵巢癌组织Ｆａｓ的表达与临床分期、组织学分级及淋巴结转移无关（Ｐ＞０．０５）；ＦａｓＬ的表达与临床分期无关但随组织学分级的升高而增加（Ｐ＜０．０５），有淋巴结转移者ＦａｓＬ的表达明显高于无淋巴结转移者（Ｐ＜０．０５）。卵巢癌ＴＩＬ中Ｆａｓ及ＦａｓＬ的表达与各临床病理参数无关（Ｐ＞０．０５）。结论：上皮性卵巢癌组织中存在Ｆａｓ表达下调和ＦａｓＬ表达增加，ＦａｓＬ高表达者预后不良。肿瘤细胞可能通过ＦａｓＬ的过度表达，逃避免疫监视，诱导Ｆａｓ敏感的
To detect the expression of Fas and FasL in epithelial ovarian cancer and its tumor infiltrating lymphocytes (TIL), and to explore the role of Fas system in the immune escape of ovarian cancer. Methods: The expressions of Fas and FasL in 31 epithelial ovarian carcinomas, 20 benign ovarian tumors, 10 normal ovarian tissues, 31 ovarian cancer TILs and 12 benign ovarian tumors were detected by flow cytometry. Results: The expression of Fas in ovarian cancer tissues was significantly lower than that in benign ovarian tumors and normal ovarian tissues (P <0.01), and the expression of FasL in ovarian cancer tissues was significantly higher than that in benign ovarian tumors and normal tissues Fas, Fas L expression was no difference (P> 0.05). Ovarian cancer tissue is rich in TIL, the expression of Fas and FasL is significantly higher than the TIL of benign ovarian tumors, the difference was significant (P> 0.05). The expression of Fas in ovarian cancer tissue had no correlation with clinical stage, histological grade and lymph node metastasis (P> 0.05). The expression of FasL was not related to clinical stage but increased with the increase of histological grade (P <0.05) The expression of FasL in patients with lymph node metastasis was significantly higher than those without lymph node metastasis (P <0.05). The expression of Fas and FasL in TIL of ovarian cancer had no correlation with clinicopathological parameters (P> 0.05). Conclusion: The expression of Fas in epithelial ovarian cancer is down-regulated and the expression of FasL is increased. The high expression of FasL is associated with poor prognosis. Tumor cells may be over-expressed by FasL, evade immune surveillance, and induce Fas-responsiveness